Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel S Childs

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
Cancer Treatment Reviews|June 26, 2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L Hertz, Daniel S Childs, Susanna B Park, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Neurologic Symptoms After <sup>177</sup>Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center ExperienceGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
Cancers|March 14, 2026
PSA Zero Radiographic Disease Progression on PSMA PET/CTAhmed M Mahmoud, Carter Day, Eman E Ahmed, et al.
The Prostate|October 30, 2023
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasisAhmed M Mahmoud, Daniel S Childs, Mohamed E Ahmed, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
Frontiers in Oncology|July 29, 2024
Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer <sup>177</sup>Lu-PSMA-617 therapyGokce Belge Bilgin, Cem Bilgin, Daniel S Childs, et al.
European Urology Open Science|July 23, 2024
Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?Mohamed E Ahmed, Ahmed M Mahmoud, Guiseppe Reitano, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
Cancer Treatment Reviews|June 26, 2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L Hertz, Daniel S Childs, Susanna B Park, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Neurologic Symptoms After <sup>177</sup>Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center ExperienceGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
Cancers|March 14, 2026
PSA Zero Radiographic Disease Progression on PSMA PET/CTAhmed M Mahmoud, Carter Day, Eman E Ahmed, et al.
The Prostate|October 30, 2023
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasisAhmed M Mahmoud, Daniel S Childs, Mohamed E Ahmed, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
Frontiers in Oncology|July 29, 2024
Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer <sup>177</sup>Lu-PSMA-617 therapyGokce Belge Bilgin, Cem Bilgin, Daniel S Childs, et al.
European Urology Open Science|July 23, 2024
Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?Mohamed E Ahmed, Ahmed M Mahmoud, Guiseppe Reitano, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
Pageof 6